The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials
Abstract
This study analyzed the natural history and prognostic factors of patients with nonsurgical hepatocellular carcinoma (HCC). Twenty variables from 102 cirrhotic patients with HCC who were not treated within prospective randomized controlled trials (RCT) were investigated through uni– and multivariate analyses. None of them was suitable for radical therapies (surgical resection, liver transplantation, or ethanol injection) or presented end–stage disease as reflected by an Okuda stage 3 or a Performance Status ≥3. Sixty–five patients were Child–Pugh A, 34 were B, and 3 were C. Most of them exhibited a preserved Performance Status Test (PST) (0 = 56; 1 = 38; 2 = 8). Tumor was solitary in 26 (≤5 cm in 16) and multinodular/massive in 76. After a median follow–up of 17 months, 79 patients died, the 1–, 2–, and 3–year survival being 54%, 40%, and 28%. The multivariate study identified PST (P = .01), constitutional syndrome (P = .04), vascular invasion (P = .001), and extrahepatic spread (P = .04) as independent predictors for mortality. The 1–, 2–, and 3–year survival for the 48 patients without adverse factors (Stage 0) was 80%, 65%, and 50%, respectively, and 29%, 16%, and 8% in the 54 patients with at least one adverse parameter (Stage I). Therefore, Stage 0 would correspond to an intermediate stage, while Stage I would represent an advanced status, before reaching an end–stage phase. In conclusion, the outcome of nonsurgical HCC is not homogeneously grim and may be predicted by assessing the presence of symptoms and of an invasive tumoral pattern. Therapeutic trials should be designed and evaluated considering these characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
The treatment of portal hypertension: A meta-analytic review
D'amico, G., Pagliaro, L., & Bosch, J. (1995) · Hepatology · doi:10.1002/hep.1840220145 · Cited by 1,015
Bruix, J., Castells, A., Bosch, J., Feu, F., Fuster, J., Garcia-Pagan, J., Visa, J., Bru, C., & Rodes, J. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70070-7 · Cited by 895
Self-citation(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Self-citationPerformance status assessment in cancer patients. An inter-observer variability study
Sørensen, J., Klee, M., Palshof, T., & Hansen, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.140 · Cited by 483
Barbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., Rigamonti, A., Barbara, C., Grigioni, W., Mazziotti, A., et al. (1992) · Hepatology · doi:10.1002/hep.1840160122 · Cited by 431
Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications
Sheu, J.-C., Sung, J.-L., Chen, D.-S., Yang, P.-M., Lai, M.-Y., Lee, C.-S., Hsu, H.-C., Chuang, C.-N., Yang, P.-C., Wang, T.-H., et al. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90324-5 · Cited by 427
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Analysis of heterogeneous outcomes within 25 RCT (2 year survival 8–50%) [131,133,139,163] HCC”
BackgroundClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationLlovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationLlovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Self-citationLo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Self-citationPrognostic prediction and treatment strategy in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2002) · Hepatology · doi:10.1053/jhep.2002.32089 · Cited by 1,099
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Self-citationBruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Self-citationSINGAL, A., VOLK, M. L., WALJEE, A., SALGIA, R., HIGGINS, P., ROGERS, M. A. M., & MARRERO, J. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04014.x · Cited by 819
Singal, A. G., Pillai, A., & Tiro, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001624 · Cited by 817
“Patients detected at an early stage can achieve 5-year survival rates of 70% with transplant or resection, whereas those with advanced HCC are only eligible for palliative treatments and have a median survival of less than one year [3,4].”
BackgroundPercutaneous radiofrequency ablation for hepatocellular carcinoma: An analysis of 1000 cases
Tateishi, R., Shiina, S., Teratani, T., Obi, S., Sato, S., Koike, Y., Fujishima, T., Yoshida, H., Kawabe, T., & Omata, M. (2005) · Cancer · doi:10.1002/cncr.20892 · Cited by 778
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Self-citationMarrero, J. A., Fontana, R. J., Su, G. L., Conjeevaram, H. S., Emick, D. M., & Lok, A. S. (2002) · Hepatology · doi:10.1002/hep.1840360609 · Cited by 660
Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., & Sherman, M. (2001) · Gut · doi:10.1136/gut.48.2.251 · Cited by 643
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Self-citationKulik, L. M., Carr, B. I., Mulcahy, M. F., Lewandowski, R. J., Atassi, B., Ryu, R. K., Sato, K. T., Benson, A., Nemcek, A. A., Gates, V. L., et al. (2008) · Hepatology · doi:10.1002/hep.21980 · Cited by 620
Hepatocellular carcinoma: Diagnosis and treatment
Befeler, A. S., & di Bisceglie, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33411 · Cited by 602
He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., Zhou, Y., Wu, X., Xu, L., Wei, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0250 · Cited by 548
Updated treatment approach to hepatocellular carcinoma
Llovet, J. M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1566-3 · Cited by 508
Self-citationTreatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Self-citationIkai, I., Arii, S., Kojiro, M., Ichida, T., Makuuchi, M., Matsuyama, Y., Nakanuma, Y., Okita, K., Omata, M., Takayasu, K., et al. (2004) · Cancer · doi:10.1002/cncr.20426 · Cited by 451
Yoon, S. M., Ryoo, B.-Y., Lee, S. J., Kim, J. H., Shin, J. H., An, J. H., Lee, H. C., & Lim, Y.-S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5847 · Cited by 446
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernandez-Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397
Self-citationSumie, S., Kuromatsu, R., Okuda, K., Ando, E., Takata, A., Fukushima, N., Watanabe, Y., Kojiro, M., & Sata, M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9846-9 · Cited by 386
Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma
Huang, J., Deng, Q., Wang, Q., Li, K.-Y., Dai, J.-H., Li, N., Zhu, Z.-D., Zhou, B., Liu, X.-Y., Liu, R.-F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2391 · Cited by 385
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
Sapisochin, G., Goldaracena, N., Laurence, J. M., Dib, M., Barbas, A., Ghanekar, A., Cleary, S. P., Lilly, L., Cattral, M. S., Marquez, M., et al. (2016) · Hepatology · doi:10.1002/hep.28643 · Cited by 368
Grazi, G. L., Ercolani, G., Pierangeli, F., Del Gaudio, M., Cescon, M., Cavallari, A., & Mazziotti, A. (2001) · Annals of Surgery · doi:10.1097/00000658-200107000-00011 · Cited by 341
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
Sayiner, M., Golabi, P., & Younossi, Z. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05537-2 · Cited by 339
Transarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Majno, P. E., Sarasin, F. P., Mentha, G., & Hadengue, A. (2000) · Hepatology · doi:10.1053/he.2000.5763 · Cited by 326
Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma
MONTALTO, G., CERVELLO, M., GIANNITRAPANI, L., DANTONA, F., TERRANOVA, A., & CASTAGNETTA, L. A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04090.x · Cited by 312
Singal, A. G., Mukherjee, A., Elmunzer, J. B., Higgins, P. D. R., Lok, A. S., Zhu, J., Marrero, J. A., & Waljee, A. K. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.332 · Cited by 305
Germani, G., Pleguezuelo, M., Gurusamy, K., Meyer, T., Isgrò, G., & Burroughs, A. K. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.004 · Cited by 304
Pawlik, T. M., Reyes, D. K., Cosgrove, D., Kamel, I. R., Bhagat, N., & Geschwind, J.-F. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1021 · Cited by 304
Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden
Nguyen, V. T. T., Law, M. G., & Dore, G. J. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01117.x · Cited by 302
Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review
Singal, A. G., Yopp, A., S. Skinner, C., Packer, M., Lee, W. M., & Tiro, J. A. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1952-x · Cited by 288
Llovet, J. M. (2002) · Gut · doi:10.1136/gut.50.1.123 · Cited by 287
Self-citationDuBay, D., Sandroussi, C., Sandhu, L., Cleary, S., Guba, M., Cattral, M. S., McGilvray, I., Ghanekar, A., Selzner, M., Greig, P. D., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820508f1 · Cited by 286
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
Self-citationSarasin, F. P., Majno, P. E., Llovet, J. M., Bruix, J., Mentha, G., & Hadengue, A. (2001) · Hepatology · doi:10.1053/jhep.2001.23311 · Cited by 263
Self-citationLevy, I., & Sherman, M. (2002) · Gut · doi:10.1136/gut.50.6.881 · Cited by 254
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Self-citationArguedas, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)06049-5 · Cited by 252
Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248
Self-citation
Metadata
- Authors
- Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J.
- Venue
- Hepatology
- Published
- 1999-01
- Volume
- 29
- Issue
- 1
- Pages
- 62-67
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2163557371
- Cited by
- 1,190
- References
- 25
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.